Zepteon, Inc. is a privately held corporation founded in 2012 that has developed first in class chromatography resins capable of separating antibodies with specific sugar structures (nonfucosylated) that are more potent against diseases like cancer. This technology enables more effective therapeutics and can reduce cost and dosing requirements.